Patients with Plaque Erosion: Management without Stenting

This small study presented at ESC and simultaneously published in the European Heart Journal evaluated patients undergoing acute coronary syndrome caused by plaque erosion identified by optical computed tomography (OCT). The study showed it can be managed with conservative antithrombotic therapy and without stenting.

 

Patients with plaque erosion can receive dual antiplatelet therapy, ticagrelor and aspirin plus and antithrombotic, which significantly reduces thrombus volume and increase minimal lumen area of the affected vessel, without increasing the risk of ischemic events within 30 days.

 

This study assessed 492 patients undergoing ACS and 458 were analyzed by OCT was done in 458. 405 culprit lesions were found, and 103 were caused by plaque erosion.

 

All patients received aspirin, ticagrelor and unfractionated heparin prior catheterization and more than 80% underwent thrombectomy (according to operators’ criteria).

 

Original Title: Effective antithrombotic therapy without stenting: intravascular OCT-based management in plaque erosion (the EROSION study).

Presenter: Jang I-K.

 

We value your opinion. You are more than welcome to leave your comments, thoughts, questions or suggestions here below.

More articles by this author

Andexanet Alfa: a Good Antidote against Anti Xa Agents

Andexanet alfa induces rapid reversion of Xa inhibitor effect in patients with active major bleeding, according to preliminary observations of the ongoing study ANNEXA-4,...

DES: Best Option in Saphenous Vein Grafts

These results confirm that, despite being used less and less worldwide, DES (drug eluting stents) are the best option in saphenous vein grafts.   Saphenous vein...

OCT Improves Outcomes in Non ST Elevation ACS

This study presented at the ESC and simultaneously published in Circulation, is the first randomized controlled study to support the use of optical coherence...

Six Month DAPT Enough for Nobori BES

Patients treated with A9 biolimus eluting stent with biodegradable polymer (Nobori, Terumo) can receive only six months of dual antiplatelet therapy (DAPT) with no...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....